Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro

Abstract

Patients with type 2 diabetes mellitus (T2DM) exhibit hyperglycemia and hyperinsulinemia and increased risk of fracture at early stage, but they were found to have normal or even enhanced bone mineral density (BMD). This study was aimed to examine the molecular mechanisms governing changes in bone structure and integrity under both hyperglycemic and hyperinsulinemic conditions. Monocytes were isolated from the bone marrow of the C57BL/6 mice, induced to differentiate into osteoclasts by receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) and exposed to high glucose (33.6 mmol/L), high insulin (1 μmol/L), or a combination of high glucose/high insulin (33.6 mmol/L glucose and 1 μmol/L insulin). Cells cultured in α-MEM alone served as control. After four days of incubation, the cells were harvested and stained for tartrate resistant acid phosphatase (TRAP). Osteoclast-related genes including RANK, cathepsin K and TRAP were determined by using real-time PCR. The resorptive activity of osteoclasts was measured by using a pit formation assay. Osteoclasts that were derived from monocytes were of multinucleated nature and positive for TRAP, a characteristic marker of osteoclasts. Cell counting showed that the number of osteoclasts was much less in high glucose and high glucose/high insulin groups than in normal glucose and high insulin groups. The expression levels of RANK and cathepsin K were significantly decreased in high glucose, high insulin and high glucose/high insulin groups as compared with normal glucose group, and the TRAP activity was substantially inhibited in high glucose environment. The pit formation assay revealed that the resorptive activity of osteoclasts was obviously decreased in high glucose group and high glucose/high insulin group as compared with normal group. It was concluded that osteoclastogenesis is suppressed under hyperglycemic and hyperinsulinemic conditions, suggesting a disruption of the bone metabolism in diabetic patients.

Keywords

osteoclastogenesis / glucose / insulin / type 2 diabetes mellitus

References

[1] RosenP, NawrothPP, KingG, et al.. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev, 2001, 17(3): 189-212

[2] YaturuS. Diabetes and skeletal health. J Diabetes, 2009, 1(4): 246-254

[3] VestergaardP. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int, 2007, 18(4): 427-444

[4] HamannC, GoettschC, MettelsiefenJ, et al.. Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab, 2011, 301(6): E1220-1228

[5] OkazakiR, MiuraM, ToriumiM, et al.. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J, 1999, 46(6): 795-801

[6] ShockleyKR, LazarenkoOP, CzernikPJ, et al.. PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem, 2009, 106(2): 232-246

[7] HieM, IitsukaN, OtsukaT, et al.. Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. Int J Mol Med, 2011, 28(3): 455-462

[8] NakasatoYR, JanckilaAJ, HalleenJM, et al.. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem, 1999, 45(12): 2150-2157

[9] YangL, Perez-AmodioS, Barrere-de GrootFY, et al.. The effects of inorganic additives to calcium phosphate on in vitro behavior of osteoblasts and osteoclasts. Biomaterials, 2010, 31(11): 2976-2989

[10] JanghorbaniM, Van DamRM, WillettWC, et al.. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol, 2007, 166(5): 495-505

[11] LiZ, KongK, QiW. Osteoclast and its roles in calcium metabolism and bone development and remodeling. Biochem Biophys Res Commun, 2006, 343(2): 345-350

[12] RaiszLG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest, 2005, 115(12): 3318-3325

[13] BoyleWJ, SimonetWS, LaceyDL. Osteoclast differentiation and activation. Nature, 2003, 423(6937): 337-342

[14] RaunerM, SiposW, PietschmannP. Osteoimmunology. Int Arch Allergy Immunol, 2007, 143(1): 31-48

[15] SiposW, PietschmannP, RaunerM, et al.. Pathophysiology of osteoporosis. Wien Med Wochenschr, 2009, 159(9–10): 230-234

[16] GopalakrishnanV, VigneshRC, ArunakaranJ, et al.. Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem Cell Biol, 2006, 84(1): 93-101

[17] ZhenD, ChenY, TangX. Metformin reverses the deleterious effects of high glucose on osteoblast function. J Diabetes Complications, 2010, 24(5): 334-344

[18] FreudeT, BraunKF, HaugA, et al.. Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-beta. J Mol Med (Berl), 2012, 90(11): 1257-1266

[19] FerronM, WeiJ, YoshizawaT, et al.. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell, 2010, 142(2): 296-308

[20] WittrantY, GorinY, WoodruffK, et al.. High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone, 2008, 42(6): 1122-1130

[21] HuangS, KawM, HarrisMT, et al.. Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone, 2010, 46(4): 1138-1145